The hydrocephalus market has witnessed substantial growth and transformative changes in recent years, according to market overview analyses. Hydrocephalus is a medical condition characterized by the accumulation of cerebrospinal fluid in the brain, leading to increased intracranial pressure. The hydrocephalus market analysis reveals a surge in demand for advanced diagnostic and treatment solutions, driven by an increasing prevalence of hydrocephalus across various age groups.
Technological advancements in medical imaging and diagnostic procedures have played a pivotal role in enhancing the early detection of hydrocephalus, contributing to the overall market growth. Moreover, the rising awareness about neurological disorders, coupled with a growing elderly population, has fueled the demand for innovative therapies and surgical interventions.
The competitive landscape of the Hydrocephalus Market is dynamic, with key players focusing on research and development to introduce novel treatment options. Collaborations and strategic partnerships between pharmaceutical companies and research institutions are also on the rise, aiming to bring forth groundbreaking therapies.
Global Hydrocephalus Market - Competitive Landscape
The global hydrocephalus market is observed to be growing due to rising prevalence of hydrocephalus in pediatric population and adults. North America dominates the market owing to well-developed healthcare sector and presence of key players like Codman & Shurtleff Inc., Integra Lifescience Holding Corporation, and Medtronic fuels the market growth in this region. The key players in the global hydrocephalus market have strategy of maintaining their position in the market through mergers and acquisitions, strategic tie-ups, new product launches and regional expansion.
Segmentation Analysis:
The hydrocephalus market is segmented by type, diagnosis, treatment, and end-user.
By type, congenital hydrocephalus held 36% share in 2017, followed by acquired hydrocephalus (31%), normal-pressure hydrocephalus (19%), and ex-vacuo hydrocephalus (14%).
By diagnosis, MRI can display 4.93% CAGR during the assessment period to reach a value of USD 659.86 million.
By treatment, surgery-shunt insertion accounted for 59% market share in 2017, followed by ventriculostomy (22%), medication (12%), and others (7%).
By end-user, diagnostic centers can exhibit 4.92% CAGR during the assessment period to touch a value of USD 397.28 million. Hospitals & clinics can generate USD 951.56 million at a CAGR of 4.12% CAGR throughout the forecast period.
Regional Analysis
The American region is the largest market for Ventriculomegaly due to the presence of well-developed healthcare sector and rising prevalence of hydrocephalus. The Americas are divided into North America and South America. Globally, North America dominates the market owing to the presence of developed economies like Canada and United States in this region. Moreover, rising healthcare expenditure, growing pediatric population and increasing awareness of the disease fuels the market growth in this region.
Europe is the second largest market for hydrocephalus due to growing patient population, increasing research and development and increasing in pediatric population. On regional basis, Europe is divided into Eastern Europe and Western Europe. Eastern Europe is rapidly growing region followed by Western Europe.
Asia Pacific is projected to be the fastest growing region owing to the presence of developing economies like China, India, Australia and increasing expenditure in healthcare.
The Middle East and Africa is the least growing region in hydrocephalus market. The Middle East region makes majority of the market due to the presence of developed economies like Saudi Arabia, Dubai, Kuwait and other developed countries within the region. African region has least market share due to lack of awareness and poor economic conditions.
For More Information Visit @ Market Research Future